Please ensure Javascript is enabled for purposes of website accessibility

Canopy Growth Rolls Out New Line of CBD Topicals

By Eric Volkman – Apr 20, 2020 at 1:45PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The three cannabidiol creams will be sold under the company's First & Free brand.

Canada-based Canopy Growth (CGC -1.80%) is expanding its brand footprint in the U.S. The cannabis company announced Monday that it's rolling out the first line of topical products within its First & Free cannabidiol (CBD) brand.

Its three new creams -- Everyday, Motion, and Revitalize -- are each packed with 2,500 milligrams of CBD per 1.76-ounce tube. Canopy Growth (citing information from Brightfield Research Group) says that makes them the highest strength CBD topical creams sold in the U.S., with over five times the concentration of competing topicals.

A field of hemp.

Image source: Getty Images.

First & Free is the marijuana company's U.S.-exclusive CBD product line. It was launched in December, nearly one year after the 2018 Farm Bill legalized products made from hemp and CBD, a non-psychoactive compound found within the plant that  is purported to have medicinal properties. Following legalization, a market quickly sprang up throughout the country for CBD products.

"With our new line of topical creams, First & Free is building a portfolio to treat the everyday stressors that affect both body and mind," Canopy Growth said in a press release. The creams are available online with two-day shipping. Each retails for $39.99 per tube.

A tube of First & Free Everyday topical.

Image source: First & Free (Canopy Growth).

Although CBD product manufacturers routinely tout the health benefits of their wares, regulators have a less enthusiastic view. Last year, the Food and Drug Administration issued a consumer update on the substance in which it noted that "there is very limited available information about CBD, including about its effects on the body."

Canopy Growth stock was trading up by 0.5% in mid-afternoon trading on Monday, while the broader equities market as measured by the S&P 500 was down by about 1.2%.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Canopy Growth Stock Quote
Canopy Growth
CGC
$2.73 (-1.80%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.